Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.
| Revenue (Most Recent Fiscal Year) | $3.24B |
| Net Income (Most Recent Fiscal Year) | $-3.56B |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.30 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.08 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -95.68% |
| Net Margin (Trailing 12 Months) | -94.31% |
| Return on Equity (Trailing 12 Months) | -25.96% |
| Return on Assets (Trailing 12 Months) | -20.09% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.93 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.77 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 6.52 |
| Book Value per Share (Most Recent Fiscal Quarter) | $28.33 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-2.13 |
| Earnings per Share (Most Recent Fiscal Year) | $-8.87 |
| Diluted Earnings per Share (Trailing 12 Months) | $-7.53 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 390.58M |
| Free Float | 347.62M |
| Market Capitalization | $10.16B |
| Average Volume (Last 20 Days) | 10.08M |
| Beta (Past 60 Months) | 2.01 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 11.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 75.33% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |